Patents by Inventor Ye Edward Tian

Ye Edward Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Fused Heteroaromatic Compounds as Kinase Inhibitors and the Use Thereof
    Publication number: 20190358225
    Abstract: The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A4, B1-B3, D1-D4 and R1-R3 are defined herein. Compounds having Formula I are kinalse inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 28, 2019
    Inventors: Suixiong CAI, Ye Edward TIAN
  • 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES
    Publication number: 20190308984
    Abstract: Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.
    Type: Application
    Filed: November 16, 2017
    Publication date: October 10, 2019
    Inventors: Sui Xiong CAI, Ye Edward TIAN
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof
    Publication number: 20190270732
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: IMPACT Therapeutics, Inc.
    Inventors: Sui Xiong CAI, Ye Edward TIAN, Haijun DONG, Qingbing XU, Lizhen WU, Lijun LIU, Yangzhen JIANG, Qingli BAO, Guoxiang WANG, Feng YIN, Chengyun GU, Xiuhua HU, Xiaozhu WANG, Sishun KANG, Shengzhi CHEN
  • APPLICATION OF HEDGEHOG PATHWAY INHIBITOR IN TREATING FIBROSIS DISEASES
    Publication number: 20190255042
    Abstract: This disclosure relates to application of hedgehog pathway inhibitor in treatment for fibrosis diseases. Specifically, the disclosure provides a method for treating and preventing fibrosis diseases. The method mentioned includes administering subjects in need with an effective amount of a hedgehog pathway inhibitor, wherein said hedgehog pathway inhibitor is a compound represented by the Formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 22, 2019
    Inventors: Sui Xiong CAI, Ye Edward TIAN
  • 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
    Patent number: 10316027
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 11, 2019
    Assignee: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof
    Publication number: 20180215741
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Sui Xiong CAI, Ye Edward TIAN, Haijun DONG, Qingbing XU, Lizhen WU, Lijun LIU, Yangzhen JIANG, Qingli BAO, Guoxiang WANG, Feng YIN, Chengyun GU, Xiuhua HU, Xiaozhu WANG, Sishun KANG, Shengzhi CHEN
  • 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
    Patent number: 9926304
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 27, 2018
    Assignee: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 1-(Arylmethyl)quinazoline-2,4(1,3)-diones as PARP inhibitors and the use thereof
    Patent number: 9290460
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: March 31, 2012
    Date of Patent: March 22, 2016
    Assignee: IMPACT THERAPEUTICS, INC.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Xiuhua Hu
  • 3-aryl-6-aryl-[1,2,4]triazolo[4,3-?]pyridines as inhibitors of cell proliferation and the use thereof
    Patent number: 9199983
    Abstract: Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines thereof, represented by the Formula (I) wherein Ar1, Ar2, R1-R3 are defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: December 1, 2015
    Inventors: Suixiong Cai, Ye Edward Tian, Haijun Dong, Lei Chen, Zenghui Yu, Feng Yin, Sheng Bi, Lijun Liu, Lizhen Wu
  • 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
    Patent number: 9102631
    Abstract: Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula 1: wherein Ar, A, R1, R3-R6 are defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: August 11, 2015
    Assignee: IMPACT Therapeutics, Inc.
    Inventors: Suixiong Cai, Ye Edward Tian, Lizhen Wu, Lijun Liu, Xiaozhu Wang, Yangzhen Jiang, Guoxiang Wang, Xiuyan Zhang, Qingbing Xu, Zheng Meng
  • Rage fusion proteins and methods of use
    Patent number: 8877192
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: November 4, 2014
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • 1-(Arylmethyl)-5,6,7,8-tetrahydroquinazolline-2,4-diones and Analogs and the Use Thereof
    Publication number: 20140275711
    Abstract: Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula I, wherein Ar, A, B, R3-R6 are defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 18, 2014
    Inventors: Suixiong Cai, Ye Edward Tian, Lizhen Wu, Lijun Liu, Xiaozhu Wang, Yangzhen Jiang, Guoxiang Wang, Xiuyan Zhang, Qingbing Xu, Zheng Meng
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof
    Publication number: 20140023642
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: March 31, 2012
    Publication date: January 23, 2014
    Applicant: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof
    Publication number: 20130280245
    Abstract: Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-?]pyridines thereof, represented by the Formula (I) wherein Ar1, Ar2, R1—R3 are defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: November 16, 2011
    Publication date: October 24, 2013
    Applicant: IMPACT Therapeutics, Inc.
    Inventors: Suixiong Cai, Ye Edward Tian, Haijun Dong, Lei Chen, Zenghui Yu, Feng Yin, Sheng Bi, Lijun Liu, Lizhen Wu
  • Nucleic acid molecules encoding rage fusion proteins
    Patent number: 8344120
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 1, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20120171202
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 3, 2011
    Publication date: July 5, 2012
    Inventors: ADNAN M.M. MJALLI, YE EDWARD TIAN, JEFFREY C. WEBSTER, ROBERT ROTHLEIN
  • Rage Fusion Proteins, Formulations And Methods Of Use Thereof
    Publication number: 20110282035
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 17, 2011
    Inventors: Adnan M.M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110244516
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: February 17, 2011
    Publication date: October 6, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • RAGE fusion proteins, formulations, and methods of use thereof
    Patent number: 7981424
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: July 19, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110124102
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 26, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein